Stem Cell Therapy for Inflammatory Diseases: Progress, Challenges, and Future Directions

Abstract

Inflammatory diseases, encompassing conditions like inflammatory bowel disease and rheumatoid arthritis, present a significant clinical challenge with substantial treatment-refractory patient populations despite biologic therapy advances. Stem cell therapeutics have emerged as a transformative approach, leveraging multifaceted regenerative mechanisms to address the complex pathophysiology of these conditions, which involves genetic, microbial, immunological, and epithelial dysregulation. This review focuses on comparing the clinical efficacy of contemporary stem cell strategies. We analyze outcomes across diverse cell sources, with a detailed examination of delivery methodologies. Our systematic analysis demonstrates superior efficacy with targeted delivery systems, particularly in managing localized inflammatory lesions (e.g., fistulas) and tissue restoration. Notably, minimally processed cellular interventions, such as autologous fat grafting and stromal vascular fraction therapy, show unexpected therapeutic promise. Critical translational barriers include suboptimal cell homing, limited engraftment persistence, and uncharacterized long-term safety profiles. We propose strategic solutions through induced pluripotent stem cell platforms, precision genetic modifications, and advanced delivery technologies. By integrating mechanistic insights with robust clinical evidence, this review establishes an evidence-based framework for optimizing stem cell therapeutics in inflammatory disease management. The analysis addresses fundamental scalability and safety considerations while identifying promising avenues for personalized regenerative medicine approaches in treatment-refractory inflammatory conditions.

Keywords

hematopoietic stem cell / hematopoietic stem cell transplantation / induced pluripotent stem cell / inflammatory disease / inflammatory bowel disease / mesenchymal stem cell

References

[1] D. Piovani, S. Danese, L. Peyrin-Biroulet, G. K. Nikolopoulos, T. Lytras, and S. Bonovas, “Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-Analyses,” Gastroenterology 157, no. 3 (2019): 647–659.e4.

[2] W. T. Uniken Venema, M. D. Voskuil, G. Dijkstra, R. K. Weersma, and E. A. Festen, “The Genetic Background of Inflammatory Bowel Disease: From Correlation to Causality,” The Journal of Pathology 241, no. 2 (2017): 146–158.

[3] A. Akhil, R. Bansal, K. Anupam, A. Tandon, and A. Bhatnagar, “Systemic Lupus erythematosus: Latest Insight Into Etiopathogenesis,” Rheumatology International 43, no. 8 (2023): 1381–1393.

[4] S. C. Ng, H. Y. Shi, N. Hamidi, et al., “Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21st Century: A Systematic Review of Population-Based Studies,” Lancet (London, England) 390, no. 10114 (2017): 2769–2778.

[5] M. Zhao, H. Zhai, H. Li, et al., “Age-Standardized Incidence, Prevalence, and Mortality Rates of Autoimmune Diseases in Adolescents and Young Adults (15-39 years): An Analysis Based on the Global Burden of Disease Study 2021,” BMC Public Health [Electronic Resource] 24, no. 1 (2024): 1800.

[6] A. Damião, M. F. C. de Azevedo, A. S. Carlos, M. Y. Wada, T. V. M. Silva, and F. C. Feitosa, “Conventional Therapy for Moderate to Severe Inflammatory Bowel Disease: A Systematic Literature Review,” World Journal of Gastroenterology 25, no. 9 (2019): 1142–1157.

[7] P. S. Dulai, S. Singh, V. Jairath, E. Wong, and N. Narula, “Integrating Evidence to Guide Use of Biologics and Small Molecules for Inflammatory Bowel Diseases,” Gastroenterology (2023), https://doi.org/10.1053/j.gastro.2023.10.033. Nov 8.

[8] A. Fanouriakis, M. Kostopoulou, J. Andersen, et al., “EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update,” Annals of the Rheumatic Diseases 83, no. 1 (2024): 15–29.

[9] J. T. Chang, “Pathophysiology of Inflammatory Bowel Diseases,” The New England Journal of Medicine 383, no. 27 (2020): 2652–2664.

[10] F. Bonella and P. Spagnolo, and C. Ryerson, “Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis,” Drugs 83, no. 17 (2023): 1581–1593.

[11] S. L. Friedman and M. Pinzani, “Hepatic fibrosis 2022: Unmet Needs and a Blueprint for the Future,” Hepatology (Baltimore, Md) 75, no. 2 (2022): 473–488.

[12] W. Zakrzewski, M. Dobrzyński, M. Szymonowicz, and Z. Rybak, “Stem Cells: Past, Present, and Future,” Stem Cell Research & Therapy 10, no. 1 (2019): 68.

[13] S. Barrère-Lemaire, A. Vincent, C. Jorgensen, C. Piot, J. Nargeot, and F. Djouad, “Mesenchymal Stromal Cells for Improvement of Cardiac Function Following Acute Myocardial Infarction: A Matter of Timing,” Physiological Reviews 104, no. 2 (2024): 659–725.

[14] A. Vazir, K. Fox, J. Westaby, M. J. Evans, and S. Westaby, “Can We Remove Scar and Fibrosis From Adult human Myocardium?,” European Heart Journal 40, no. 12 (2019): 960–966.

[15] A. Psaraki, L. Ntari, C. Karakostas, D. Korrou-Karava, and M. G. Roubelakis, “Extracellular Vesicles Derived From Mesenchymal Stem/Stromal Cells: The Regenerative Impact in Liver Diseases,” Hepatology (Baltimore, Md) 75, no. 6 (2022): 1590–1603.

[16] M. Alfaifi, Y. W. Eom, P. N. Newsome, and S. K. Baik, “Mesenchymal Stromal Cell Therapy for Liver Diseases,” Journal of Hepatology 68, no. 6 (2018): 1272–1285.

[17] M. Lopez-Santalla, J. A. Bueren, and M. I. Garin, “Mesenchymal Stem/Stromal Cell-Based Therapy for the Treatment of Rheumatoid Arthritis: An Update on Preclinical Studies,” EBioMedicine 69 (2021): 103427.

[18] Z. Lin, Y. Wu, Y. Xu, G. Li, Z. Li, and T. Liu, “Mesenchymal Stem Cell-Derived Exosomes in Cancer Therapy Resistance: Recent Advances and Therapeutic Potential,” Molecular Cancer 21, no. 1 (2022): 179.

[19] S. Ikehara, T. Nakamura, K. Sekita, et al., “Treatment of Systemic and Organ-Specific Autoimmune Disease in Mice by Allogeneic Bone Marrow Transplantation,” Progress in Clinical and Biological Research 229 (1987): 131–146.

[20] T. Ishida, M. Inaba, H. Hisha, et al., “Requirement of Donor-Derived Stromal Cells in the Bone Marrow for Successful Allogeneic Bone Marrow Transplantation. Complete Prevention of Recurrence of Autoimmune Diseases in MRL/MP-Ipr/Ipr Mice by Transplantation of Bone Marrow plus Bones (stromal cells) From the Same Donor,” Journal of Immunology (Baltimore, Md: 1950) 152, no. 6 (1994): 3119–3127.

[21] J. A. Yin and S. N. Jowitt, “Resolution of Immune-Mediated Diseases Following Allogeneic Bone Marrow Transplantation for Leukaemia,” Bone Marrow Transplantation 9, no. 1 (1992): 31–33.

[22] A. M. Marmont, “Historical Perspectives, Rationale and Future Directions for Hematopoietic Stem Cell Transplantation for Severe Autoimmune Diseases,” Haematologica 87, no. 8 Suppl (2002): 24–27.

[23] X. Yuan and L. Sun, “Stem Cell Therapy in Lupus,” Rheumatology and Immunology Research 3, no. 2 (2022): 61–68.

[24] C. Picard, H. Bobby Gaspar, W. Al-Herz, et al., “International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity,” Journal of Clinical Immunology 38, no. 1 (2018): 96–128.

[25] E. O. Glocker, D. Kotlarz, K. Boztug, et al., “Inflammatory Bowel Disease and Mutations Affecting the Interleukin-10 Receptor,” The New England Journal of Medicine 361, no. 21 (2009): 2033–2045.

[26] C. Speckmann, K. Lehmberg, M. H. Albert, et al., “X-Linked Inhibitor of Apoptosis (XIAP) Deficiency: The Spectrum of Presenting Manifestations Beyond Hemophagocytic Lymphohistiocytosis,” Clinical Immunology (Orlando, Fla) 149, no. 1 (2013): 133–141.

[27] H. H. Uhlig, T. Schwerd, S. Koletzko, et al., “The Diagnostic Approach to Monogenic Very Early Onset Inflammatory Bowel Disease,” Gastroenterology 147, no. 5 (2014): 990–1007.e3.

[28] R. A. Marsh, J. W. Leiding, B. R. Logan, et al., “Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT,” Journal of Clinical Immunology 39, no. 7 (2019): 653–667.

[29] M. Morita, I. Takeuchi, M. Kato, et al., “Intestinal Outcome of Bone Marrow Transplantation for Monogenic Inflammatory Bowel Disease,” Pediatrics International: Official Journal of the Japan Pediatric Society (2021), https://doi.org/10.1111/ped.14750. Apr 21.

[30] C. G. Vinuesa, N. Shen, and T. Ware, “Genetics of SLE: Mechanistic Insights From Monogenic Disease and Disease-Associated Variants,” Nature Reviews Nephrology 19, no. 9 (2023): 558–572.

[31] H. Buso, E. Adam, P. D. Arkwright, et al., “Hematopoietic Stem Cell Transplantation for C1q Deficiency: A Study on Behalf of the EBMT Inborn Errors Working Party,” Journal of Clinical Immunology 45, no. 1 (2024): 35.

[32] F. Yang, B. Ni, Q. Liu, et al., “Human Umbilical Cord-Derived Mesenchymal Stem Cells Ameliorate Experimental Colitis by Normalizing the Gut Microbiota,” Stem Cell Research & Therapy 13, no. 1 (2022): 475.

[33] S. Soontararak, L. Chow, V. Johnson, et al., “Mesenchymal Stem Cells (MSC) Derived From Induced Pluripotent Stem Cells (iPSC) Equivalent to Adipose-Derived MSC in Promoting Intestinal Healing and Microbiome Normalization in Mouse Inflammatory Bowel Disease Model,” Stem Cells Translational Medicine 7, no. 6 (2018): 456–467.

[34] Q. Shen, Z. Huang, J. Yao, and Y. Jin, “Extracellular Vesicles-Mediated Interaction Within Intestinal Microenvironment in Inflammatory Bowel Disease,” Journal of Advanced Research 37 (2022): 221–233.

[35] M. M. Zaiss, H. J. Joyce Wu, D. Mauro, G. Schett, and F. Ciccia, “The Gut-Joint Axis in Rheumatoid Arthritis,” Nature Reviews Rheumatology 17, no. 4 (2021): 224–237.

[36] E. Miyauchi, C. Shimokawa, A. Steimle, M. S. Desai, and H. Ohno, “The Impact of the Gut Microbiome on Extra-Intestinal Autoimmune Diseases,” Nature Reviews Immunology 23, no. 1 (2023): 9–23.

[37] Y. Zhao, B. Chen, S. Li, et al., “Detection and Characterization of Bacterial Nucleic Acids in Culture-Negative Synovial Tissue and Fluid Samples From Rheumatoid Arthritis or Osteoarthritis Patients,” Scientific Reports 8, no. 1 (2018): 14305.

[38] P. A. Muraro, D. C. Douek, A. Packer, et al., “Thymic Output Generates a New and Diverse TCR Repertoire After Autologous Stem Cell Transplantation in Multiple Sclerosis Patients,” The Journal of Experimental Medicine 201, no. 5 (2005): 805–816.

[39] S. T. Roord, W. de Jager, L. Boon, et al., “Autologous Bone Marrow Transplantation in Autoimmune Arthritis Restores Immune Homeostasis Through CD4+CD25+Foxp3+ Regulatory T Cells,” Blood 111, no. 10 (2008): 5233–5241.

[40] T. Alexander, A. Thiel, O. Rosen, et al., “Depletion of Autoreactive Immunologic Memory Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Refractory SLE Induces Long-Term Remission Through De Novo Generation of a Juvenile and Tolerant Immune System,” Blood 113, no. 1 (2009): 214–223.

[41] Y. Shi, Y. Wang, Q. Li, et al., “Immunoregulatory Mechanisms of Mesenchymal Stem and Stromal Cells in Inflammatory Diseases,” Nature Reviews Nephrology 14, no. 8 (2018): 493–507.

[42] E. Gonzalez-Rey, P. Anderson, M. A. González, L. Rico, D. Büscher, and M. Delgado, “Human Adult Stem Cells Derived From Adipose Tissue Protect Against Experimental Colitis and Sepsis,” Gut 58, no. 7 (2009): 929–939.

[43] L. Li, S. Liu, Y. Xu, et al., “Human Umbilical Cord-Derived Mesenchymal Stem Cells Downregulate Inflammatory Responses by Shifting the Treg/Th17 Profile in Experimental Colitis,” Pharmacology 92, no. 5-6 (2013): 257–264.

[44] K. Chao, S. Zhang, Y. Qiu, et al., “Human Umbilical Cord-Derived Mesenchymal Stem Cells Protect Against Experimental Colitis via CD5(+) B Regulatory Cells,” Stem Cell Research & Therapy 7, no. 1 (2016): 109.

[45] Y. Li, K. Ma, L. Zhang, H. Xu, and N. Zhang, “Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells Alleviate Dextran Sulfate Sodium-Induced Colitis by Increasing Regulatory T Cells in Mice,” Frontiers in Cell and Developmental Biology 8 (2020): 604021.

[46] W. J. Song, Q. Li, M. O. Ryu, et al., “TSG-6 Released From Intraperitoneally Injected Canine Adipose Tissue-Derived Mesenchymal Stem Cells Ameliorate Inflammatory Bowel Disease by Inducing M2 Macrophage Switch in Mice,” Stem Cell Research & Therapy 9, no. 1 (2018): 91.

[47] Y. Kawata, A. Tsuchiya, S. Seino, et al., “Early Injection of human Adipose Tissue-Derived Mesenchymal Stem Cell After Inflammation Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice Through the Induction of M2 Macrophages and Regulatory T Cells,” Cell and Tissue Research 376, no. 2 (2019): 257–271.

[48] H. Jo, Y. W. Eom, H. S. Kim, H. J. Park, H. M. Kim, and M. Y. Cho, “Regulatory Dendritic Cells Induced by Mesenchymal Stem Cells Ameliorate Dextran Sodium Sulfate-Induced Chronic Colitis in Mice,” Gut and Liver 12, no. 6 (2018): 664–673.

[49] A. Nikolic, B. Simovic Markovic, and M. Gazdic, “Intraperitoneal Administration of Mesenchymal Stem Cells Ameliorates Acute Dextran Sulfate Sodium-Induced Colitis by Suppressing Dendritic Cells,” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 100 (2018): 426–432.

[50] Y. Lu, Y. Xu, S. Zhang, et al., “Human Gingiva-Derived Mesenchymal Stem Cells Alleviate Inflammatory Bowel Disease via IL-10 Signalling-Dependent Modulation of Immune Cells,” Scandinavian Journal of Immunology 90, no. 3 (2019): e12751.

[51] Y. Hayashi, S. Tsuji, M. Tsujii, et al., “Topical Implantation of Mesenchymal Stem Cells Has Beneficial Effects on Healing of Experimental Colitis in Rats,” The Journal of Pharmacology and Experimental Therapeutics 326, no. 2 (2008): 523–531.

[52] C. Nie, D. Yang, J. Xu, Z. Si, X. Jin, and J. Zhang, “Locally Administered Adipose-Derived Stem Cells Accelerate Wound Healing Through Differentiation and Vasculogenesis,” Cell Transplantation 20, no. 2 (2011): 205–216.

[53] T. Yabana, Y. Arimura, H. Tanaka, et al., “Enhancing Epithelial Engraftment of Rat Mesenchymal Stem Cells Restores Epithelial Barrier Integrity,” The Journal of Pathology 218, no. 3 (2009): 350–359.

[54] H. Yang, R. Feng, Q. Fu, et al., “Human Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Promote Healing via TNF-α-Stimulated Gene-6 in Inflammatory Bowel Disease Models,” Cell Death & Disease 10, no. 10 (2019): 718.

[55] J. Xu, X. Wang, J. Chen, et al., “Embryonic Stem Cell-Derived Mesenchymal Stem Cells Promote Colon Epithelial Integrity and Regeneration by Elevating Circulating IGF-1 in Colitis Mice,” Theranostics 10, no. 26 (2020): 12204–12222.

[56] S. F. Ahmed, S. A. Jasim, H. Pallathadka, et al., “New Therapeutic Strategies for the Inflammatory Rheumatoid Arthritis Disease: Emphasizing Mesenchymal Stem Cells and Associated Exo-miRNA or Exo-lncRNA,” Cell Biochemistry and Biophysics 82, no. 3 (2024): 1599–1611.

[57] Z. Chen, H. Wang, Y. Xia, F. Yan, and Y. Lu, “Therapeutic Potential of Mesenchymal Cell-Derived miRNA-150-5p-Expressing Exosomes in Rheumatoid Arthritis Mediated by the Modulation of MMP14 and VEGF,” Journal of Immunology (Baltimore, Md: 1950) 201, no. 8 (2018): 2472–2482.

[58] J. Zhang, Y. Zhang, Y. Ma, L. Luo, M. Chu, and Z. Zhang, “Therapeutic Potential of Exosomal circRNA Derived From Synovial Mesenchymal Cells via Targeting circEDIL3/miR-485-3p/PIAS3/STAT3/VEGF Functional Module in Rheumatoid Arthritis,” International Journal of Nanomedicine 16 (2021): 7977–7994.

[59] Y. Lin, L. Lin, Q. Wang, et al., “Transplantation of human Umbilical Mesenchymal Stem Cells Attenuates Dextran Sulfate Sodium-Induced Colitis in Mice,” Clinical and Experimental Pharmacology & Physiology 42, no. 1 (2015): 76–86.

[60] J. G. Gao, M. S. Yu, M. M. Zhang, et al., “Adipose-Derived Mesenchymal Stem Cells Alleviate TNBS-Induced Colitis in Rats by Influencing Intestinal Epithelial Cell Regeneration, Wnt Signaling, and T Cell Immunity,” World Journal of Gastroenterology 26, no. 26 (2020): 3750–3766.

[61] Y. S. Lee, S. K. Sah, J. H. Lee, K. W. Seo, K. S. Kang, and T. Y. Kim, “Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Ameliorate Psoriasis-Like Skin Inflammation in Mice,” Biochem Biophys Rep 9 (2017): 281–288.

[62] J. Y. Kim, M. Park, Y. H. Kim, et al., “Tonsil-Derived Mesenchymal Stem Cells (T-MSCs) Prevent Th17-Mediated Autoimmune Response via Regulation of the Programmed Death-1/Programmed Death Ligand-1 (PD-1/PD-L1) Pathway,” J Tissue Eng Regen Med 12, no. 2 (2018): e1022–e1033.

[63] Y. Chen, Y. Hu, X. Zhou, et al., “Human Umbilical Cord-Derived Mesenchymal Stem Cells Ameliorate Psoriasis-Like Dermatitis by Suppressing IL-17-Producing ΓδT Cells,” Cell and Tissue Research 388, no. 3 (2022): 549–563.

[64] H. S. Kim, J. W. Yun, T. H. Shin, et al., “Human Umbilical Cord Blood Mesenchymal Stem Cell-Derived PGE2 and TGF-β1 Alleviate Atopic Dermatitis by Reducing Mast Cell Degranulation,” Stem cells (Dayton, Ohio) 33, no. 4 (2015): 1254–1266.

[65] T. H. Shin, B. C. Lee, S. W. Choi, et al., “Human Adipose Tissue-Derived Mesenchymal Stem Cells Alleviate Atopic Dermatitis via Regulation of B Lymphocyte Maturation,” Oncotarget 8, no. 1 (2017): 512–522.

[66] J. Y. Song, H. J. Kang, H. M. Ju, et al., “Umbilical Cord-Derived Mesenchymal Stem Cell Extracts Ameliorate Atopic Dermatitis in Mice by Reducing the T Cell Responses,” Scientific reports 9, no. 1 (2019): 6623.

[67] H. H. Park, S. Lee, Y. Yu, et al., “TGF-β Secreted by human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Ameliorates Atopic Dermatitis by Inhibiting Secretion of TNF-α and IgE,” Stem cells (Dayton, Ohio) 38, no. 7 (2020): 904–916.

[68] N. Jung, T. Kong, Y. Yu, et al., “Immunomodulatory Effect of Epidermal Growth Factor Secreted by Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells on Atopic Dermatitis,” International Journal of Stem Cells 15, no. 3 (2022): 311–323.

[69] Y. Ma, Z. Wang, A. Zhang, et al., “Human Placenta-Derived Mesenchymal Stem Cells Ameliorate GVHD by Modulating Th17/Tr1 Balance via Expression of PD-L2,” Life sciences 214 (2018): 98–105.

[70] W. Zhuoya, Z. Nannan, Z. Aiping, et al., “Human Placenta Derived Mesenchymal Stromal Cells Alleviate GVHD by Promoting the Generation of GSH and GST in PD-1(+)T Cells,” Cellular immunology 352 (2020): 104083.

[71] J. Zhang, Y. Zhao, H. Zhang, et al., “Human Placental Mesenchymal Stromal Cells Modulate IFN-γ and IL-10 Secretion by CD4(+)T Cells via CD73, and Alleviate Intestinal Damage in Mice With Graft-Versus-Host Disease,” International immunopharmacology 124, no. Pt A (2023): 110767.

[72] H. Zhang, K. Han, H. Li, et al., “hPMSCs Regulate the Level of TNF-α and IL-10 in Th1 Cells and Improve Hepatic Injury in a GVHD Mouse Model via CD73/ADO/Fyn/Nrf2 Axis,” Inflammation 47, no. 1 (2024): 244–263.

[73] Y. Zhao, Z. Chen, Y. Wu, et al., “Human Placental Mesenchymal Stromal Cells Promote the Formation of CD8(+)CD122(+)PD-1(+)Tregs via CD73/Foxo1 to Alleviate Liver Injury in Graft-Versus-Host Disease Mice,” International immunopharmacology 138 (2024): 112554.

[74] W. Yan, H. Zhang, J. Zhang, et al., “Human Placental Mesenchymal Stem Cells Regulate the Antioxidant Capacity of CD8(+)PD-1(+) T Cells Through the CD73/ADO/Nrf2 Pathway to Protect Against Liver Damage in Mice With Acute Graft-Versus-Host Disease,” Molecular immunology 179 (2025): 71–83.

[75] B. Zhou, J. Yuan, Y. Zhou, et al., “Administering human Adipose-Derived Mesenchymal Stem Cells to Prevent and Treat Experimental Arthritis,” Clinical immunology (Orlando, Fla) 141, no. 3 (2011): 328–337.

[76] H. Yi, K. Y. Kang, Y. Kim, et al., “Human Adipose-Derived Mesenchymal Stem Cells Attenuate Collagen Antibody-Induced Autoimmune Arthritis by Inducing Expression of FCGIIB Receptors,” BMC Musculoskeletal Disorders 16 (2015): 170.

[77] M. Zhang, T. K. Johnson-Stephenson, and W. Wang, “Mesenchymal Stem Cell-Derived Exosome-Educated Macrophages Alleviate Systemic Lupus Erythematosus by Promoting Efferocytosis and Recruitment of IL-17(+) Regulatory T Cell,” Stem Cell Research & Therapy 13, no. 1 (2022): 484.

[78] W. Sun, S. Yan, C. Yang, et al., “Mesenchymal Stem Cells-Derived Exosomes Ameliorate Lupus by Inducing M2 Macrophage Polarization and Regulatory T Cell Expansion in MRL/Lpr Mice,” Immunological Investigations 51, no. 6 (2022): 1785–1803.

[79] F. Guo, Q. Pan, T. Chen, et al., “hUC-MSC Transplantation Therapy Effects on Lupus-Prone MRL/Lpr Mice at Early Disease Stages,” Stem Cell Research & Therapy 14, no. 1 (2023): 211.

[80] B. Fang, Y. Song, L. Liao, Y. Zhang, and R. C. Zhao, “Favorable Response to human Adipose Tissue-Derived Mesenchymal Stem Cells in Steroid-Refractory Acute Graft-Versus-Host Disease,” Transplantation Proceedings 39, no. 10 (2007): 3358–3362.

[81] K. Le Blanc, F. Frassoni, L. Ball, et al., “Mesenchymal Stem Cells for Treatment of Steroid-Resistant, Severe, Acute Graft-Versus-Host Disease: A Phase II Study,” Lancet (London, England) 371, no. 9624 (2008): 1579–1586.

[82] J. A. Pérez-Simon, O. López-Villar, E. J. Andreu, et al., “Mesenchymal Stem Cells Expanded in Vitro With human Serum for the Treatment of Acute and Chronic Graft-Versus-Host Disease: Results of a Phase I/II Clinical Trial,” Haematologica 96, no. 7 (2011): 1072–1076.

[83] R. Herrmann, M. Sturm, K. Shaw, et al., “Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute and Chronic Graft versus Host Disease: A Phase 1 Study,” International journal of hematology 95, no. 2 (2012): 182–188.

[84] I. B. Resnick, C. Barkats, M. Y. Shapira, et al., “Treatment of Severe Steroid Resistant Acute GVHD With Mesenchymal Stromal Cells (MSC),” American journal of blood research 3, no. 3 (2013): 225–238.

[85] M. Introna, G. Lucchini, E. Dander, et al., “Treatment of Graft versus Host Disease With Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients,” Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 20, no. 3 (2014): 375–381.

[86] K. Muroi, K. Miyamura, M. Okada, et al., “Bone Marrow-Derived Mesenchymal Stem Cells (JR-031) for Steroid-Refractory Grade III or IV Acute Graft-Versus-Host Disease: A Phase II/III Study,” International journal of hematology 103, no. 2 (2016): 243–250.

[87] G. M. Dotoli, G. C. De Santis, M. D. Orellana, et al., “Mesenchymal Stromal Cell Infusion to Treat Steroid-Refractory Acute GvHD III/IV After Hematopoietic Stem Cell Transplantation,” Bone marrow transplantation 52, no. 6 (2017): 859–862.

[88] S. Servais, F. Baron, C. Lechanteur, et al., “Infusion of Bone Marrow Derived Multipotent Mesenchymal Stromal Cells for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease: A Multicenter Prospective Study,” Oncotarget 9, no. 29 (2018): 20590–20604.

[89] P. Bader, Z. Kuçi, S. Bakhtiar, et al., “Effective Treatment of Steroid and Therapy-Refractory Acute Graft-Versus-Host Disease With a Novel Mesenchymal Stromal Cell Product (MSC-FFM),” Bone marrow transplantation 53, no. 7 (2018): 852–862.

[90] P. Kebriaei, J. Hayes, A. Daly, et al., “A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease,” Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 26, no. 5 (2020): 835–844.

[91] A. J. C. Bloor, A. Patel, J. E. Griffin, et al., “Production, Safety and Efficacy of iPSC-Derived Mesenchymal Stromal Cells in Acute Steroid-Resistant Graft versus Host Disease: A Phase I, Multicenter, Open-Label, Dose-Escalation Study,” Nature Medicine 26, no. 11 (2020): 1720–1725.

[92] R. P. Soder, B. Dawn, M. L. Weiss, et al., “A Phase I Study to Evaluate Two Doses of Wharton's Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft versus Host Disease,” Stem cell reviews and reports 16, no. 5 (2020): 979–991.

[93] H. Fu, X. Sun, R. Lin, et al., “Mesenchymal Stromal Cells plus Basiliximab Improve the Response of Steroid-Refractory Acute Graft-Versus-Host Disease as a Second-Line Therapy: A Multicentre, Randomized, Controlled Trial,” BMC medicine 22, no. 1 (2024): 85.

[94] E. Jiang, K. Qian, L. Wang, et al., “Efficacy and Safety of human Umbilical Cord-Derived Mesenchymal Stem Cells versus Placebo Added to Second-Line Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: A Multicentre, Randomized, Double-Blind, Phase 2 Trial,” BMC medicine 22, no. 1 (2024): 555.

[95] A. Bukauskas, R. Jucaitienė, M. Stoškus, et al., “Mesenchymal Stromal Cells for Steroid-Refractory Biopsy-Proven Grade III-IV Acute Graft-Versus-Host Disease With Predominant Gastrointestinal Involvement,” Frontiers in immunology 16 (2025): 1600019.

[96] Y. Zhao, Y. Luo, J. Shi, et al., “Salvage Treatment of Steroid-Refractory Acute GVHD With the off-the-Shelf Product of human Umbilical Cord Mesenchymal Stromal Cells: A Multicenter, Open Label, Phase Ib/IIa Trial,” Stem cell research & therapy 16, no. 1 (2025): 345.

[97] M. Duijvestein, A. C. Vos, H. Roelofs, et al., “Autologous Bone Marrow-Derived Mesenchymal Stromal Cell Treatment for Refractory Luminal Crohn's Disease: Results of a Phase I Study,” Gut 59, no. 12 (2010): 1662–1669.

[98] L. B. Lazebnik, O. V. Kniazev, A. G. Konopliannikov, et al., “Allogeneic Mesenchymal Stromal Cells in Patients With Ulcerative Colitis: Two Years of Observation,” Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, no. 11 (2010): 3–15.

[99] J. Liang, H. Zhang, D. Wang, et al., “Allogeneic Mesenchymal Stem Cell Transplantation in Seven Patients With Refractory Inflammatory Bowel Disease,” Gut 61, no. 3 (2012): 468–469.

[100] G. M. Forbes, M. J. Sturm, R. W. Leong, et al., “A Phase 2 Study of Allogeneic Mesenchymal Stromal Cells for Luminal Crohn's Disease Refractory to Biologic Therapy,” Clinical Gastroenterology and Hepatology 12, no. 1 (2014): 64–71.

[101] J. Hu, G. Zhao, L. Zhang, et al., “Safety and Therapeutic Effect of Mesenchymal Stem Cell Infusion on Moderate to Severe Ulcerative Colitis. Experimental and Therapeutic Medicine,” Nov 12, no. 5 (2016): 2983–2989.

[102] T. Dhere, I. Copland, M. Garcia, et al., “The Safety of Autologous and Metabolically Fit Bone Marrow Mesenchymal Stromal Cells in Medically Refractory Crohn's Disease—a Phase 1 Trial With Three Doses,” Alimentary pharmacology & therapeutics 44, no. 5 (2016): 471–481.

[103] C. Gregoire, A. Briquet, C. Pirenne, C. Lechanteur, E. Louis, and Y. Beguin, “Allogeneic Mesenchymal Stromal Cells for Refractory Luminal Crohn's Disease: A Phase I-II Study,” Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 50, no. 11 (2018): 1251–1255.

[104] J. Zhang, S. Lv, X. Liu, B. Song, and L. Shi, “Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease: A Randomized Controlled Clinical Trial,” Gut and liver 12, no. 1 (2018): 73–78.

[105] J. Liang, H. Zhang, B. Hua, et al., “Allogenic Mesenchymal Stem Cells Transplantation in Refractory Systemic Lupus erythematosus: A Pilot Clinical Study,” Annals of the rheumatic diseases 69, no. 8 (2010): 1423–1429.

[106] L. Sun, D. Wang, J. Liang, et al., “Umbilical Cord Mesenchymal Stem Cell Transplantation in Severe and Refractory Systemic Lupus Erythematosus,” Arthritis and rheumatism 62, no. 8 (2010): 2467–2475.

[107] X. Li, D. Wang, J. Liang, H. Zhang, and L. Sun, “Mesenchymal SCT Ameliorates Refractory Cytopenia in Patients With Systemic Lupus Erythematosus,” Bone marrow transplantation 48, no. 4 (2013): 544–550.

[108] D. Wang, J. Li, Y. Zhang, et al., “Umbilical Cord Mesenchymal Stem Cell Transplantation in Active and Refractory Systemic Lupus Erythematosus: A Multicenter Clinical Study,” Arthritis research & therapy 16, no. 2 (2014): R79.

[109] F. Gu, D. Wang, H. Zhang, et al., “Allogeneic Mesenchymal Stem Cell Transplantation for lupus Nephritis Patients Refractory to Conventional Therapy,” Clinical rheumatology 33, no. 11 (2014): 1611–1619.

[110] D. Deng, P. Zhang, Y. Guo, and T. O. Lim, “A Randomised Double-Blind, Placebo-Controlled Trial of Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cell for Lupus Nephritis,” Annals of the rheumatic diseases 76, no. 8 (2017): 1436–1439.

[111] D. Farge, L. Biard, B. Weil, et al., “Allogeneic Umbilical Cord-Derived Mesenchymal Stromal Cells as Treatment for Systemic Lupus Erythematosus: A Single-Centre, Open-Label, Dose-Escalation, Phase 1 Study,” The Lancet Rheumatology 7, no. 4 (2025): e261–e273.

[112] J. M. Álvaro-Gracia, J. A. Jover, R. García-Vicuña, et al., “Intravenous Administration of Expanded Allogeneic Adipose-Derived Mesenchymal Stem Cells in Refractory Rheumatoid Arthritis (Cx611): Results of a Multicentre, Dose Escalation, Randomised, Single-Blind, Placebo-Controlled Phase Ib/IIa Clinical Trial,” Annals of the rheumatic diseases 76, no. 1 (2017): 196–202.

[113] E. H. Park, H. S. Lim, S. Lee, et al., “Intravenous Infusion of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Rheumatoid Arthritis: A Phase Ia Clinical Trial,” Stem cells translational medicine 7, no. 9 (2018): 636–642.

[114] M. Ghoryani, Z. Shariati-Sarabi, J. Tavakkol-Afshari, A. Ghasemi, J. Poursamimi, and M. Mohammadi, “Amelioration of Clinical Symptoms of Patients With Refractory Rheumatoid Arthritis Following Treatment With Autologous Bone Marrow-Derived Mesenchymal Stem Cells: A Successful Clinical Trial in Iran,” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 109 (2019): 1834–1840.

[115] L. Wang, S. Huang, S. Li, et al., “Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients: A Prospective Phase I/II Study,” Drug Des Devel Ther 13 (2019): 4331–4340.

[116] D. Yao, S. Ye, Z. He, et al., “Adipose-Derived Mesenchymal Stem Cells (AD-MSCs) in the Treatment for Psoriasis: Results of a Single-Arm Pilot Trial,” Annals of translational medicine 9, no. 22 (2021): 1653.

[117] L. Cheng, S. Wang, C. Peng, et al., “Human Umbilical Cord Mesenchymal Stem Cells for Psoriasis: A Phase 1/2a, Single-Arm Study,” Signal Transduct Target Ther 7, no. 1 (2022): 263.

[118] H. T. Shin, S. H. Lee, H. S. Yoon, et al., “Long-Term Efficacy and Safety of Intravenous Injection of Clonal Mesenchymal Stem Cells Derived From Bone Marrow in Five Adults With Moderate to Severe Atopic Dermatitis,” Journal of Dermatology 48, no. 8 (2021): 1236–1242.

[119] H. M. Seo, B. L. Lew, Y. W. Lee, et al., “Phase 1/2 Trials of human Bone Marrow-Derived Clonal Mesenchymal Stem Cells for Treatment of Adults With Moderate to Severe Atopic Dermatitis,” The Journal of allergy and clinical immunology 154, no. 4 (2024): 965–973.

[120] M. K. Glassberg, J. Minkiewicz, R. L. Toonkel, et al., “Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial,” Chest 151, no. 5 (2017): 971–981.

[121] A. Averyanov, I. Koroleva, M. Konoplyannikov, et al., “First-in-Human High-Cumulative-Dose Stem Cell Therapy in Idiopathic Pulmonary Fibrosis With Rapid Lung Function Decline,” Stem cells translational medicine 9, no. 1 (2020): 6–16.

[122] K. T. Suk, J. H. Yoon, M. Y. Kim, et al., “Transplantation With Autologous Bone Marrow-Derived Mesenchymal Stem Cells for Alcoholic Cirrhosis: Phase 2 Trial,” Hepatology (Baltimore, Md) 64, no. 6 (2016): 2185–2197.

[123] M. Shi, Y. Y. Li, R. N. Xu, et al., “Mesenchymal Stem Cell Therapy in Decompensated Liver Cirrhosis: A Long-Term Follow-Up Analysis of the Randomized Controlled Clinical Trial,” Hepatology International 15, no. 6 (2021): 1431–1441.

[124] L. Shi, Z. Zhang, S. Mei, et al., “Dose-Escalation Studies of Mesenchymal Stromal Cell Therapy for Decompensated Liver Cirrhosis: Phase Ia/Ib Results and Immune Modulation Insights,” Signal Transduct Target Ther 10, no. 1 (2025): 238.

[125] O. Ringdén, M. Uzunel, I. Rasmusson, et al., “Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-Versus-Host Disease,” Transplantation 81, no. 10 (2006): 1390–1397.

[126] I. Khan, U. Rehman, F. Aslam, et al., “Efficacy and Safety of Mesenchymal Stromal Cells for Steroid-Refractory Acute Graft-Versus-Host Disease: An Updated Meta-Analysis of Randomized Controlled Trials,” (2025), https://doi.org/10.1007/s12015-025-10947-z. Jul 22.

[127] M. Döring, K. M. Cabanillas Stanchi, K. Lenglinger, et al., “Long-Term Follow-Up after the Application of Mesenchymal Stromal Cells in Children and Adolescents With Steroid-Refractory Graft-Versus-Host Disease,” Stem cells and development 30, no. 5 (2021): 234–246.

[128] K. L. Blanc, F. Dazzi, K. English, et al., “ISCT MSC Committee Statement on the US FDA Approval of Allogenic Bone-Marrow Mesenchymal Stromal Cells,” Cytotherapy 27, no. 4 (2025): 413–416.

[129] Y. A. Tsai, R. S. Liu, J. F. Lirng, et al., “Treatment of Spinocerebellar Ataxia With Mesenchymal Stem Cells: A Phase I/IIa Clinical Study,” Cell transplantation 26, no. 3 (2017): 503–512.

[130] M. Jurado, L. A. De, C. Mata, A. Ruiz-García, et al., “Adipose Tissue-Derived Mesenchymal Stromal Cells as Part of Therapy for Chronic Graft-Versus-Host Disease: A Phase I/II Study,” Cytotherapy 19, no. 8 (2017): 927–936.

[131] A. V. Vanikar, H. L. Trivedi, A. Kumar, et al., “Co-Infusion of Donor Adipose Tissue-Derived Mesenchymal and Hematopoietic Stem Cells Helps Safe Minimization of Immunosuppression in Renal Transplantation—single Center Experience,” Renal Failure 36, no. 9 (2014): 1376–1384.

[132] R. Ciccocioppo, M. E. Bernardo, A. Sgarella, et al., “Autologous Bone Marrow-Derived Mesenchymal Stromal Cells in the Treatment of Fistulising Crohn's Disease,” Gut 60, no. 6 (2011): 788–798.

[133] J. Liang, H. Zhang, C. Zhao, et al., “Effects of Allogeneic Mesenchymal Stem Cell Transplantation in the Treatment of Liver Cirrhosis Caused by Autoimmune Diseases,” International journal of rheumatic diseases 20, no. 9 (2017): 1219–1226.

[134] L. Wang, J. Li, H. Liu, et al., “Pilot Study of Umbilical Cord-Derived Mesenchymal Stem Cell Transfusion in Patients With Primary Biliary Cirrhosis,” Journal of Gastroenterology and Hepatology 28, no. Suppl 1 (2013): 85–92.

[135] D. García-Olmo, M. García-Arranz, L. G. García, et al., “Autologous Stem Cell Transplantation for Treatment of Rectovaginal Fistula in Perianal Crohn's Disease: A New Cell-Based Therapy,” International journal of colorectal disease 18, no. 5 (2003): 451–454.

[136] D. Garcia-Olmo, M. Garcia-Arranz, D. Herreros, I. Pascual, C. Peiro, and J. A. Rodriguez-Montes, “A Phase I Clinical Trial of the Treatment of Crohn's Fistula by Adipose Mesenchymal Stem Cell Transplantation,” Diseases of the Colon and Rectum 48, no. 7 (2005): 1416–1423.

[137] D. Garcia-Olmo, D. Herreros, I. Pascual, et al., “Expanded Adipose-Derived Stem Cells for the Treatment of Complex Perianal Fistula: A Phase II Clinical Trial,” Diseases of the colon and rectum 52, no. 1 (2009): 79–86.

[138] F. de la Portilla, F. Alba, D. García-Olmo, J. M. Herrerías, F. X. González, and A. Galindo, “Expanded Allogeneic Adipose-Derived Stem Cells (eASCs) for the Treatment of Complex Perianal Fistula in Crohn's disease: Results From a Multicenter Phase I/IIa Clinical Trial,” International journal of colorectal disease 28, no. 3 (2013): 313–323.

[139] Y. B. Cho, W. Y. Lee, K. J. Park, M. Kim, H. W. Yoo, and C. S. Yu, “Autologous Adipose Tissue-Derived Stem Cells for the Treatment of Crohn's Fistula: A Phase I Clinical Study,” Cell Transplantation 22, no. 2 (2013): 279–285.

[140] Y. B. Cho, K. J. Park, S. N. Yoon, et al., “Long-Term Results of Adipose-Derived Stem Cell Therapy for the Treatment of Crohn's Fistula,” Stem cells translational medicine 4, no. 5 (2015): 532–537.

[141] I. Molendijk, B. A. Bonsing, H. Roelofs, et al., “Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells Promote Healing of Refractory Perianal Fistulas in Patients With Crohn's Disease,” Gastroenterology 149, no. 4 (2015): 918–927. e6.

[142] J. Panés, D. García-Olmo, G. Van Assche, et al., “Expanded Allogeneic Adipose-Derived Mesenchymal Stem Cells (Cx601) for Complex Perianal Fistulas in Crohn's disease: A Phase 3 Randomised, Double-Blind Controlled Trial,” Lancet (London, England) 388, no. 10051 (2016): 1281–1290.

[143] M. García-Arranz, M. D. Herreros, C. González-Gómez, et al., “Treatment of Crohn's-Related Rectovaginal Fistula With Allogeneic Expanded-Adipose Derived Stem Cells: A Phase I-IIa Clinical Trial,” Stem Cells Translational Medicine 5, no. 11 (2016): 1441–1446.

[144] C. Wainstein, R. Quera, D. Fluxá, et al., “Stem Cell Therapy in Refractory Perineal Crohn's Disease: Long-Term Follow-Up,” Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland (2018), https://doi.org/10.1111/codi.14002. Jan 6.

[145] A. L. Lightner, E. J. Dozois, A. B. Dietz, et al., “Matrix-Delivered Autologous Mesenchymal Stem Cell Therapy for Refractory Rectovaginal Crohn's Fistulas,” Inflammatory bowel diseases 26, no. 5 (2020): 670–677.

[146] M. Nikolic, A. Stift, W. Reinisch, et al., “Allogeneic Expanded Adipose-Derived Stem Cells in the Treatment of Rectovaginal Fistulas in Crohn's disease,” Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland 23, no. 1 (2021): 153–158.

[147] O. Schwandner, “Stem Cell Injection for Complex Anal Fistula in Crohn's disease: A Single-Center Experience,” World journal of gastroenterology 27, no. 24 (2021): 3643–3653.

[148] Y. J. Cho, H. Kwon, Y. J. Kwon, K. M. Kim, S. H. Oh, and D. Y. Kim, “Efficacy and Safety of Autologous Adipose Tissue-Derived Stem Cell Therapy for Children With Refractory Crohn's Complex Fistula: A Phase IV Clinical Study,” Annals of surgical treatment and research 101, no. 1 (2021): 58–64.

[149] A. L. Lightner, N. Dadgar, C. Matyas, et al., “A Phase IB/IIA Study of Remestemcel-L, an Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Product, for the Treatment of Medically Refractory Ulcerative Colitis: An Interim Analysis,” Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland 24, no. 11 (2022): 1358–1370.

[150] A. L. Lightner, J. Reese, J. Ream, et al., “A Phase IB/IIA Study of Ex Vivo Expanded Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease,” Diseases of the colon and rectum 66, no. 10 (2023): 1359–1372.

[151] A. L. Lightner, A. Otero-Pineiro, J. Reese, et al., “A Phase I Study of Ex Vivo Expanded Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Pediatric Perianal Fistulizing Crohn's Disease,” Inflammatory bowel diseases 29, no. 12 (2023): 1912–1919.

[152] S. Swaroop, S. K. Vuyyuru, B. Kante, et al., “A Phase I/II Clinical Trial of Ex-Vivo Expanded human Bone Marrow Derived Allogeneic Mesenchymal Stromal Cells in Adult Patients With Perianal Fistulizing Crohn's Disease,” Stem cell research & therapy 15, no. 1 (2024): 140.

[153] Q. Sun, S. Li, R. Lin, et al., “hUC-MSCs Therapy for Crohn's disease: Efficacy in TNBS-Induced Colitis in Rats and Pilot Clinical Study,” EBioMedicine 103 (2024): 105128.

[154] J. M. Lamo-Espinosa, G. Mora, J. F. Blanco, et al., “Intra-Articular Injection of Two Different Doses of Autologous Bone Marrow Mesenchymal Stem Cells versus Hyaluronic Acid in the Treatment of Knee Osteoarthritis: Multicenter Randomized Controlled Clinical Trial (phase I/II),” Journal of translational medicine 14, no. 1 (2016): 246.

[155] J. Matas, M. Orrego, D. Amenabar, et al., “Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial,” Stem Cells Translational Medicine 8, no. 3 (2019): 215–224.

[156] J. M. Lamo-Espinosa, J. F. Blanco, M. Sánchez, et al., “Phase II Multicenter Randomized Controlled Clinical Trial on the Efficacy of Intra-Articular Injection of Autologous Bone Marrow Mesenchymal Stem Cells With Platelet Rich Plasma for the Treatment of Knee Osteoarthritis,” Journal of translational medicine 18, no. 1 (2020): 356.

[157] P. K. Gupta, S. Maheshwari, J. J. Cherian, et al., “Efficacy and Safety of Stempeucel in Osteoarthritis of the Knee: A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled Study,” The American journal of sports medicine 51, no. 9 (2023): 2254–2266.

[158] K. I. Kim, M. C. Lee, J. H. Lee, et al., “Clinical Efficacy and Safety of the Intra-Articular Injection of Autologous Adipose-Derived Mesenchymal Stem Cells for Knee Osteoarthritis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial,” The American journal of sports medicine 51, no. 9 (2023): 2243–2253.

[159] O. A. Pico, F. Espinoza, M. I. Cádiz, et al., “Efficacy of a Single Dose of Cryopreserved human Umbilical Cord Mesenchymal Stromal Cells for the Treatment of Knee Osteoarthritis:A Randomized, Controlled, Double-Blind Pilot Study,” Cytotherapy 27, no. 2 (2025): 188–200.

[160] H. S. Kim, J. H. Lee, K. H. Roh, H. J. Jun, K. S. Kang, and T. Y. Kim, “Clinical Trial of Human Umbilical Cord Blood-Derived Stem Cells for the Treatment of Moderate-To-Severe Atopic Dermatitis: Phase I/IIa Studies,” Stem cells (Dayton, Ohio) 35, no. 1 (2017): 248–255.

[161] C. Zhang, L. Huang, X. Wang, et al., “Topical and Intravenous Administration of human Umbilical Cord Mesenchymal Stem Cells in Patients With Diabetic Foot Ulcer and Peripheral Arterial Disease: A Phase I Pilot Study With a 3-Year Follow-Up,” Stem cell research & therapy 13, no. 1 (2022): 451.

[162] A. Bajouri, D. Dayani, A. Taj Sharghi, et al., “Subcutaneous Injection of Allogeneic Adipose-Derived Mesenchymal Stromal Cells in Psoriasis Plaques: Clinical Trial Phase I,” Cell J 25, no. 6 (2023): 363–371.

[163] S. Shadmanfar, N. Labibzadeh, M. Emadedin, et al., “Intra-Articular Knee Implantation of Autologous Bone Marrow-Derived Mesenchymal Stromal Cells in Rheumatoid Arthritis Patients With Knee Involvement: Results of a Randomized, Triple-Blind, Placebo-Controlled Phase 1/2 Clinical Trial,” Cytotherapy 20, no. 4 (2018): 499–506.

[164] D. A. Schwartz, E. V. Loftus, and W. J. Tremaine, “The Natural History of Fistulizing Crohn's Disease in Olmsted County, Minnesota,” Gastroenterology 122, no. 4 (2002): 875–880.

[165] T. W. Eglinton, M. L. Barclay, R. B. Gearry, and F. A. Frizelle, “The Spectrum of Perianal Crohn's Disease in a Population-Based Cohort,” Diseases of the colon and rectum 55, no. 7 (2012): 773–777.

[166] S. H. Park, S. Aniwan, W. Scott Harmsen, et al., “Update on the Natural Course of Fistulizing Perianal Crohn's Disease in a Population-Based Cohort,” Inflammatory bowel diseases 25, no. 6 (2019): 1054–1060.

[167] M. Adamina, S. Bonovas, T. Raine, et al., “ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment,” Journal of Crohn's & colitis 14, no. 2 (2020): 155–168.

[168] R. Ciccocioppo, A. Gallia, A. Sgarella, P. Kruzliak, P. G. Gobbi, and G. R. Corazza, “Long-Term Follow-Up of Crohn Disease Fistulas after Local Injections of Bone Marrow-Derived Mesenchymal Stem Cells,” Mayo Clinic proceedings 90, no. 6 (2015): 747–755.

[169] M. C. Barnhoorn, M. Wasser, H. Roelofs, et al., “Long-Term Evaluation of Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cell Therapy for Crohn's Disease Perianal Fistulas,” Journal of Crohn's & colitis 14, no. 1 (2020): 64–70.

[170] W. Tsuji, J. P. Rubin, and K. G. Marra, “Adipose-Derived Stem Cells: Implications in Tissue Regeneration,” World journal of stem cells 6, no. 3 (2014): 312–321.

[171] B. A. Bunnell, M. Flaat, C. Gagliardi, B. Patel, and C. Ripoll, “Adipose-Derived Stem Cells: Isolation, Expansion and Differentiation,” Methods (San Diego, Calif) 45, no. 2 (2008): 115–120.

[172] W. Y. Lee, K. J. Park, Y. B. Cho, et al., “Autologous Adipose Tissue-Derived Stem Cells Treatment Demonstrated Favorable and Sustainable Therapeutic Effect for Crohn's Fistula,” Stem cells (Dayton, Ohio) 31, no. 11 (2013): 2575–2581.

[173] Z. W. Meng and D. C. Baumgart, “Darvadstrocel for the Treatment of Perianal Fistulas in Crohn's disease,” Expert review of gastroenterology & hepatology 14, no. 6 (2020): 405–410.

[174] D. Garcia-Olmo, I. Gilaberte, M. Binek, et al., “Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Darvadstrocel (Mesenchymal Stem Cell Treatment) in Patients With Perianal Fistulizing Crohn's Disease: ADMIRE-CD Phase 3 Randomized Controlled Trial,” Diseases of the colon and rectum 65, no. 5 (2022): 713–720.

[175] M. Scharl and G. Rogler, “Pathophysiology of Fistula Formation in Crohn's Disease,” World journal of gastrointestinal pathophysiology 5, no. 3 (2014): 205–212.

[176] J. Panés and J. Rimola, “Perianal Fistulizing Crohn's Disease: Pathogenesis, Diagnosis and Therapy,” Nature reviews Gastroenterology & hepatology 14, no. 11 (2017): 652–664.

[177] A. B.-B.-K.-R. MM, H. Chen, X. Liu, and Y. H. Wang, “Experimental Porcine Model of Complex Fistula-In-Ano,” World journal of gastroenterology 23, no. 10 (2017): 1828–1835.

[178] J. M. Lamo-Espinosa, G. Mora, J. F. Blanco, et al., “Intra-Articular Injection of Two Different Doses of Autologous Bone Marrow Mesenchymal Stem Cells versus Hyaluronic Acid in the Treatment of Knee Osteoarthritis: Long-Term Follow up of a Multicenter Randomized Controlled Clinical Trial (phase I/II),” Journal of translational medicine 16, no. 1 (2018): 213.

[179] C. K. Brierley, C. Castilla-Llorente, M. Labopin, et al., “Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-Term Outcomes From the European Society for Blood and Marrow Transplantation,” Journal of Crohn's & colitis 12, no. 9 (2018): 1097–1103.

[180] R. K. Burt, A. Traynor, Y. Oyama, and R. Craig, “High-Dose Immune Suppression and Autologous Hematopoietic Stem Cell Transplantation in Refractory Crohn Disease,” Blood 101, no. 5 (2003): 2064–2066.

[181] Y. Oyama, R. M. Craig, A. E. Traynor, et al., “Autologous Hematopoietic Stem Cell Transplantation in Patients With Refractory Crohn's Disease,” Gastroenterology 128, no. 3 (2005): 552–563.

[182] A. Cassinotti, C. Annaloro, S. Ardizzone, et al., “Autologous Haematopoietic Stem Cell Transplantation Without CD34+ Cell Selection in Refractory Crohn's Disease,” Gut 57, no. 2 (2008): 211–217.

[183] R. K. Burt, R. M. Craig, F. Milanetti, et al., “Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Patients With Severe Anti-TNF Refractory Crohn Disease: Long-Term Follow-Up,” Blood 116, no. 26 (2010): 6123–6132.

[184] P. Hasselblatt, K. Drognitz, K. Potthoff, et al., “Remission of Refractory Crohn's Disease by High-Dose Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation,” Alimentary Pharmacology & Therapeutics 36, no. 8 (2012): 725–735.

[185] C. J. Hawkey, M. Allez, M. M. Clark, et al., “Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial,” Jama 314, no. 23 (2015): 2524–2534.

[186] A. Jauregui-Amezaga, M. Rovira, P. Marín, et al., “Improving Safety of Autologous Haematopoietic Stem Cell Transplantation in Patients With Crohn's Disease,” Gut 65, no. 9 (2016): 1456–1462.

[187] A. López-García, M. Rovira, A. Jauregui-Amezaga, et al., “Autologous Haematopoietic Stem Cell Transplantation for Refractory Crohn's Disease: Efficacy in a Single-Centre Cohort,” Journal of Crohn's & Colitis 11, no. 10 (2017): 1161–1168.

[188] M. A. Ruiz, R. L. Kaiser, L. G. de Quadros, et al., “Low Toxicity and Favorable Clinical and Quality of Life Impact After Non-Myeloablative Autologous Hematopoietic Stem Cell Transplant in Crohn's disease,” BMC Research Notes 10, no. 1 (2017): 495.

[189] J. O. Lindsay, D. Hind, L. Swaby, et al., “Safety and Efficacy of Autologous Haematopoietic Stem-Cell Transplantation With Low-Dose Cyclophosphamide Mobilisation and Reduced Intensity Conditioning versus Standard of Care in Refractory Crohn's Disease (ASTIClite): An Open-Label, Multicentre, Randomised Controlled Trial,” The lancet Gastroenterology & hepatology 9, no. 4 (2024): 333–345.

[190] J. O. Lindsay, M. Allez, M. Clark, et al., “Autologous Stem-Cell Transplantation in Treatment-Refractory Crohn's disease: An Analysis of Pooled Data From the ASTIC Trial,” The lancet Gastroenterology & Hepatology 2, no. 6 (2017): 399–406.

[191] A. G. Pockley, J. O. Lindsay, G. A. Foulds, et al., “Immune Reconstitution after Autologous Hematopoietic Stem Cell Transplantation in Crohn's Disease: Current Status and Future Directions. A Review on Behalf of the EBMT Autoimmune Diseases Working Party and the Autologous Stem Cell Transplantation in Refractory CD-Low Intensity Therapy Evaluation Study Investigators,” Frontiers in immunology 9 (2018): 646.

[192] C. J. Hawkey, J. Lindsay, and J. Gribben, “Stem Cell Transplantation for Refractory Crohn Disease–Reply,” Jama 315, no. 23 (2016): 2620–2621.

[193] J. A. Snowden, C. Hawkey, D. Hind, et al., “Autologous Stem Cell Transplantation in Refractory Crohn's Disease—low Intensity Therapy Evaluation (ASTIClite): Study Protocols for a Multicentre, Randomised Controlled Trial and Observational Follow up Study,” BMC gastroenterology 19, no. 1 (2019): 82.

[194] R. K. Burt, A. E. Traynor, R. Pope, et al., “Treatment of Autoimmune Disease by Intense Immunosuppressive Conditioning and Autologous Hematopoietic Stem Cell Transplantation,” Blood 92, no. 10 (1998): 3505–3514.

[195] A. E. Traynor, J. Schroeder, R. M. Rosa, et al., “Treatment of Severe Systemic Lupus Erythematosus With High-Dose Chemotherapy and Haemopoietic Stem-Cell Transplantation: A Phase I Study,” Lancet (London, England) 356, no. 9231 (2000): 701–707.

[196] R. K. Burt, A. Traynor, L. Statkute, et al., “Nonmyeloablative Hematopoietic Stem Cell Transplantation for Systemic Lupus Erythematosus,” Jama 295, no. 5 (2006): 527–535.

[197] C. Cao, M. Wang, J. Sun, et al., “Autologous Peripheral Blood Haematopoietic Stem Cell Transplantation for Systemic Lupus Erythematosus: The Observation of Long-Term Outcomes in a Chinese Centre,” Clinical and Experimental Rheumatology 35, no. 3 (2017): 500–507.

[198] X. Huang, W. Chen, and G. Ren, “Autologous Hematopoietic Stem Cell Transplantation for Refractory Lupus Nephritis,” Clin J Am Soc Nephrol 14, no. 5 (2019): 719–727.

[199] R. K. Burt, S. J. Shah, K. Dill, et al., “Autologous Non-Myeloablative Haemopoietic Stem-Cell Transplantation Compared With Pulse Cyclophosphamide Once per Month for Systemic Sclerosis (ASSIST): An Open-Label, Randomised Phase 2 Trial,” Lancet (London, England) 378, no. 9790 (2011): 498–506.

[200] J. M. van Laar, D. Farge, J. K. Sont, et al., “Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis: A Randomized Clinical Trial,” Jama 311, no. 24 (2014): 2490–2498.

[201] K. M. Sullivan, E. A. Goldmuntz, L. Keyes-Elstein, et al., “Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma,” The New England journal of medicine 378, no. 1 (2018): 35–47.

[202] M. Ayano, H. Tsukamoto, H. Mitoma, et al., “CD34-Selected versus Unmanipulated Autologous Haematopoietic Stem Cell Transplantation in the Treatment of Severe Systemic Sclerosis: A Post Hoc Analysis of a Phase I/II Clinical Trial Conducted in Japan,” Arthritis research & therapy 21, no. 1 (2019): 30.

[203] D. C. Talbot, A. Montes, W. L. Teh, A. Nandi, and R. L. Powles, “Remission of Crohn's Disease Following Allogeneic Bone Marrow Transplant for Acute Leukaemia,” Hospital medicine (London, England: 1998) 59, no. 7 (1998): 580–581.

[204] M. Nishimoto, H. Nakamae, K. Watanabe, et al., “Successful Treatment of both Acute Leukemia and Active Crohn's Disease After Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning With Fludarabine and Busulfan: A Case Report,” Transplantation proceedings 45, no. 7 (2013): 2854–2857.

[205] C. Hu, L. Lv, D. Liu, and J. Huo, “Treatment of Crohn's Disease Complicated With Myelodysplastic Syndrome via Allogeneic Hematopoietic Stem Cell Transplantation: Case Report and Literature Review,” Clinical journal of gastroenterology 7, no. 4 (2014): 299–304.

[206] Y. Zhang, L. L. Lou, X. D. Shi, et al., “Allogeneic Hematopoietic Stem Cell Transplantation for Crohn Disease Complicated With Myelodysplastic Syndrome: A Case Report,” Medicine 99, no. 10 (2020): e19450.

[207] Y. Leung, M. Geddes, J. Storek, R. Panaccione, and P. L. Beck, “Hematopoietic Cell Transplantation for Crohn's disease; Is It Time?,” World journal of gastroenterology 12, no. 41 (2006): 6665–6673.

[208] E. A. Worthey, A. N. Mayer, G. D. Syverson, et al., “Making a Definitive Diagnosis: Successful Clinical Application of Whole Exome Sequencing in a Child With Intractable Inflammatory Bowel Disease,” Genetics in medicine: official journal of the American College of Medical Genetics 13, no. 3 (2011): 255–262.

[209] A. Xue, X. Qian, X. Gao, et al., “Fecal Microbial Signatures Are Associated With Engraftment Failure Following Umbilical Cord Blood Transplantation in Pediatric Crohn's Disease Patients With IL10RA Deficiency,” Frontiers in pharmacology 11 (2020): 580817.

[210] R. K. Burt, R. Craig, L. Yun, et al., “A Pilot Feasibility Study of Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease,” Bone marrow transplantation 55, no. 12 (2020): 2343–2346.

[211] D. Kotlarz, R. Beier, D. Murugan, et al., “Loss of Interleukin-10 Signaling and Infantile Inflammatory Bowel Disease: Implications for Diagnosis and Therapy,” Gastroenterology 143, no. 2 (2012): 347–355.

[212] K. R. Engelhardt, N. Shah, I. Faizura-Yeop, et al., “Clinical Outcome in IL-10- and IL-10 Receptor-Deficient Patients With or Without Hematopoietic Stem Cell Transplantation,” The Journal of allergy and clinical immunology 131, no. 3 (2013): 825–830.

[213] D. Murugan, M. H. Albert, J. Langemeier, et al., “Very Early Onset Inflammatory Bowel Disease Associated With Aberrant Trafficking of IL-10R1 and Cure by T Cell Replete Haploidentical Bone Marrow Transplantation,” Journal of clinical immunology 34, no. 3 (2014): 331–339.

[214] A. Gassas, S. Courtney, C. Armstrong, E. Kapllani, A. M. Muise, and T. Schechter, “Unrelated Donor Hematopoietic Stem Cell Transplantation for Infantile Enteropathy due to IL-10/IL-10 Receptor Defect,” Pediatric transplantation 19, no. 4 (2015): E101–103.

[215] K. Kato, Y. Kojima, C. Kobayashi, et al., “Successful Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease With Inflammatory Complications and Severe Infection,” International journal of hematology 94, no. 5 (2011): 479–482.

[216] F. Hauck, S. Koletzko, C. Walz, et al., “Diagnostic and Treatment Options for Severe IBD in Female X-CGD Carriers With Non-Random X-Inactivation,” Journal of Crohn's & colitis 10, no. 1 (2016): 112–115.

[217] Y. Tsuma, T. Imamura, E. Ichise, et al., “Successful Treatment of Idiopathic Colitis Related to XIAP Deficiency With Allo-HSCT Using Reduced-Intensity Conditioning. Pediatric Transplantation,” Feb 19, no. 1 (2015): E25–E28.

[218] B. Tesi, P. Priftakis, F. Lindgren, et al., “Successful Hematopoietic Stem Cell Transplantation in a Patient With LPS-Responsive Beige-Like Anchor (LRBA) Gene Mutation,” Journal of clinical immunology 36, no. 5 (2016): 480–489.

[219] S. Bakhtiar, L. Gámez-Díaz, A. Jarisch, et al., “Treatment of Infantile Inflammatory Bowel Disease and Autoimmunity by Allogeneic Stem Cell Transplantation in LPS-Responsive Beige-Like Anchor Deficiency,” Frontiers in immunology 8 (2017): 52.

[220] T. T. Ozgür, G. T. Asal, D. Cetinkaya, et al., “Hematopoietic Stem Cell Transplantation in a CD3 Gamma-Deficient Infant With Inflammatory Bowel Disease,” Pediatric transplantation 12, no. 8 (2008): 910–913.

[221] C. Bolton, N. Burch, J. Morgan, et al., “Remission of Inflammatory Bowel Disease in Glucose-6-Phosphatase 3 Deficiency by Allogeneic Haematopoietic Stem Cell Transplantation,” Journal of Crohn's & colitis 14, no. 1 (2020): 142–147.

[222] A. Goenka, J. A. Doherty, T. Al-Farsi, et al., “Neutrophil Dysfunction Triggers Inflammatory Bowel Disease in G6PC3 Deficiency,” Journal of leukocyte biology 109, no. 6 (2021): 1147–1154.

[223] M. Wright, S. Chandrakasan, D. T. Okou, et al., “Early Onset Granulomatous Colitis Associated With a Mutation in NCF4 Resolved With Hematopoietic Stem Cell Transplantation,” The Journal of pediatrics 210 (2019): 220–225.

[224] C. H. T. Hall and E. F. de Zoeten, “Understanding Very Early Onset Inflammatory Bowel Disease (VEOIBD) in Relation to Inborn Errors of Immunity,” Immunological reviews 322, no. 1 (2024): 329–338.

[225] J. Ouahed, E. Spencer, D. Kotlarz, et al., “Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies,” Inflammatory bowel diseases 26, no. 6 (2020): 820–842.

[226] H. Buso, C. Triaille, A. M. Flinn, and A. R. Gennery, “Update on Hereditary C1q Deficiency: Pathophysiology, Clinical Presentation, Genotype and Management,” Current Opinion in Allergy and Clinical Immunology 24, no. 6 (2024): 427–433.

[227] M. Ayatollahi, B. Geramizadeh, M. Zakerinia, et al., “Human Bone Marrow-Derived Mesenchymal Stem Cell: A Source for Cell-Based Therapy,” International journal of organ transplantation medicine 3, no. 1 (2012): 32–41.

[228] F. De Francesco, G. Ricci, F. D'Andrea, G. F. Nicoletti, and G. A. Ferraro, “Human Adipose Stem Cells: From Bench to Bedside,” Tissue engineering Part B, Reviews 21, no. 6 (2015): 572–584.

[229] A. Selich, K. Zimmermann, M. Tenspolde, et al., “Umbilical Cord as a Long-Term Source of Activatable Mesenchymal Stromal Cells for Immunomodulation,” Stem cell research & therapy 10, no. 1 (2019): 285.

[230] J. S. Heo, Y. Choi, H. S. Kim, and H. O. Kim, “Comparison of Molecular Profiles of human Mesenchymal Stem Cells Derived From Bone Marrow, Umbilical Cord Blood, Placenta and Adipose Tissue,” International journal of molecular medicine 37, no. 1 (2016): 115–125.

[231] C. Y. Li, X. Y. Wu, J. B. Tong, et al., “Comparative Analysis of human Mesenchymal Stem Cells From Bone Marrow and Adipose Tissue Under Xeno-Free Conditions for Cell Therapy,” Stem cell research & therapy 6, no. 1 (2015): 55.

[232] H. J. Lee, J. Jung, K. J. Cho, C. K. Lee, S. G. Hwang, and G. J. Kim, “Comparison of in Vitro Hepatogenic Differentiation Potential Between Various Placenta-Derived Stem Cells and Other Adult Stem Cells as an Alternative Source of Functional Hepatocytes,” Differentiation; research in biological diversity 84, no. 3 (2012): 223–231.

[233] A. Ootani, X. Li, E. Sangiorgi, et al., “Sustained in Vitro Intestinal Epithelial Culture Within a Wnt-Dependent Stem Cell Niche,” Nature medicine 15, no. 6 (2009): 701–706.

[234] J. H. Won, J. S. Choi, and J. I. Jun, “CCN1 interacts With Integrins to Regulate Intestinal Stem Cell Proliferation and Differentiation,” Nature communications 13, no. 1 (2022): 3117.

[235] T. Sato, R. G. Vries, H. J. Snippert, et al., “Single Lgr5 Stem Cells Build Crypt-Villus Structures in Vitro Without a Mesenchymal Niche,” Nature 459, no. 7244 (2009): 262–265.

[236] I. Dotti, R. Mora-Buch, E. Ferrer-Picón, et al., “Alterations in the Epithelial Stem Cell Compartment Could Contribute to Permanent Changes in the Mucosa of Patients With Ulcerative Colitis,” Gut 66, no. 12 (2017): 2069–2079.

[237] K. Suzuki, T. Murano, H. Shimizu, et al., “Single Cell Analysis of Crohn's Disease Patient-Derived Small Intestinal Organoids Reveals Disease Activity-Dependent Modification of Stem Cell Properties,” Journal of gastroenterology 53, no. 9 (2018): 1035–1047.

[238] C. Lee, S. N. Hong, E. R. Kim, D. K. Chang, and Y. H. Kim, “Epithelial Regeneration Ability of Crohn's Disease Assessed Using Patient-Derived Intestinal Organoids,” International journal of molecular sciences 22, no. 11 (2021), https://doi.org/10.3390/ijms22116013.

[239] J. H. Yoo and M. Donowitz, “Intestinal Enteroids/Organoids: A Novel Platform for Drug Discovery in Inflammatory Bowel Diseases,” World journal of gastroenterology 25, no. 30 (2019): 4125–4147.

[240] T. H. Kang and H. J. Kim, “Farewell to Animal Testing: Innovations on Human Intestinal Microphysiological Systems,” Micromachines 7, no. 7 (2016), https://doi.org/10.3390/mi7070107.

[241] S. Yui, T. Nakamura, T. Sato, et al., “Functional Engraftment of Colon Epithelium Expanded in Vitro From a Single Adult Lgr5⁺ Stem Cell,” Nature medicine 18, no. 4 (2012): 618–623.

[242] M. Fukuda, T. Mizutani, W. Mochizuki, et al., “Small Intestinal Stem Cell Identity Is Maintained With Functional Paneth Cells in Heterotopically Grafted Epithelium Onto the Colon,” Genes & Development 28, no. 16 (2014): 1752–1757.

[243] T. Sato, J. H. van Es, H. J. Snippert, et al., “Paneth Cells Constitute the Niche for Lgr5 Stem Cells in Intestinal Crypts,” Nature 469, no. 7330 (2011): 415–418.

[244] N. Sasaki and N. Sachs, K. Wiebrands, et al., “Reg4+ deep Crypt Secretory Cells Function as Epithelial Niche for Lgr5+ Stem Cells in Colon,” Proceedings of the National Academy of Sciences of the United States of America 113, no. 37 (2016): E5399–E5407.

[245] L. Meran, I. Massie, S. Campinoti, et al., “Engineering Transplantable Jejunal Mucosal Grafts Using Patient-Derived Organoids From Children With Intestinal Failure,” Nature medicine 26, no. 10 (2020): 1593–1601.

[246] T. Hirsch, T. Rothoeft, N. Teig, et al., “Regeneration of the Entire human Epidermis Using Transgenic Stem Cells,” Nature 551, no. 7680 (2017): 327–332.

[247] K. Abe, A. Yamashita, M. Morioka, et al., “Engraftment of Allogeneic iPS Cell-Derived Cartilage Organoid in a Primate Model of Articular Cartilage Defect,” Nature communications 14, no. 1 (2023): 804.

[248] T. Tadokoro, S. Murata, M. Kato, et al., “Human iPSC-Liver Organoid Transplantation Reduces Fibrosis Through Immunomodulation,” Science Translational Medicine 16, no. 757 (2024): eadg0338.

[249] S. Yamanaka, “Induced Pluripotent Stem Cells: Past, Present, and Future,” Cell stem cell 10, no. 6 (2012): 678–684.

[250] M. Hansen, E. Varga, C. Aarts, et al., “Efficient Production of Erythroid, Megakaryocytic and Myeloid Cells, Using Single Cell-Derived iPSC Colony Differentiation,” Stem cell research 29 (2018): 232–244.

[251] B. Romano, S. Elangovan, M. Erreni, et al., “TNF-Stimulated Gene-6 Is a Key Regulator in Switching Stemness and Biological Properties of Mesenchymal Stem Cells,” Stem cells (Dayton, Ohio) 37, no. 7 (2019): 973–987.

[252] E. Sala, M. Genua, L. Petti, et al., “Mesenchymal Stem Cells Reduce Colitis in Mice via Release of TSG6, Independently of Their Localization to the Intestine,” Gastroenterology 149, no. 1 (2015): 163–176.e20.

[253] D. Hoffmann, J. Sens, S. Brennig, et al., “Genetic Correction of IL-10RB Deficiency Reconstitutes Anti-Inflammatory Regulation in iPSC-Derived Macrophages,” Journal of personalized medicine 11, no. 3 (2021), https://doi.org/10.3390/jpm11030221. Mar 20.

[254] J. Sens, D. Hoffmann, L. Lange, et al., “Knockout-Induced Pluripotent Stem Cells for Disease and Therapy Modeling of IL-10-Associated Primary Immunodeficiencies,” Human gene therapy 32, no. 1-2 (2021): 77–95.

[255] J. P. Gleeson, H. Q. Estrada, M. Yamashita, C. N. Svendsen, S. R. Targan, and R. J. Barrett, “Development of Physiologically Responsive Human iPSC-Derived Intestinal Epithelium to Study Barrier Dysfunction in IBD,” International journal of molecular sciences 21, no. 4 (2020), https://doi.org/10.3390/ijms21041438. Feb 20.

[256] M. J. Workman, E. Troisi, S. R. Targan, C. N. Svendsen, and R. J. Barrett, “Modeling Intestinal Epithelial Response to Interferon-γ in Induced Pluripotent Stem Cell-Derived Human Intestinal Organoids,” International journal of molecular sciences 22, no. 1 (2020), https://doi.org/10.3390/ijms22010288. Dec 30.

[257] K. Kelly, A. J. C. Bloor, J. E. Griffin, R. Radia, D. T. Yeung, and J. E. J. Rasko, “Two-Year Safety Outcomes of iPS Cell-Derived Mesenchymal Stromal Cells in Acute Steroid-Resistant Graft-Versus-Host Disease,” Nature medicine 30, no. 6 (2024): 1556–1558.

[258] I. Harasymiak-Krzyżanowska, A. Niedojadło, J. Karwat, et al., “Adipose Tissue-Derived Stem Cells Show Considerable Promise for Regenerative Medicine Applications,” Cellular & molecular biology letters 18, no. 4 (2013): 479–493.

[259] M. Serrero, F. Grimaud, C. Philandrianos, C. Visée, F. Sabatier, and J. C. Grimaud, “Long-Term Safety and Efficacy of Local Microinjection Combining Autologous Microfat and Adipose-Derived Stromal Vascular Fraction for the Treatment of Refractory Perianal Fistula in Crohn's Disease,” Gastroenterology 156, no. 8 (2019): 2335–2337.e2.

[260] H. Suga, H. Eto, N. Aoi, et al., “Adipose Tissue Remodeling Under Ischemia: Death of Adipocytes and Activation of Stem/Progenitor Cells,” Plastic and reconstructive surgery 126, no. 6 (2010): 1911–1923.

[261] H. Suga, H. Eto, T. Shigeura, et al., “IFATS Collection: Fibroblast Growth Factor-2-Induced Hepatocyte Growth Factor Secretion by Adipose-Derived Stromal Cells Inhibits Postinjury Fibrogenesis Through a c-Jun N-Terminal Kinase-Dependent Mechanism,” Stem cells (Dayton, Ohio) 27, no. 1 (2009): 238–249.

[262] J. A. Rophael, R. O. Craft, J. A. Palmer, et al., “Angiogenic Growth Factor Synergism in a Murine Tissue Engineering Model of Angiogenesis and Adipogenesis,” The American journal of pathology 171, no. 6 (2007): 2048–2057.

[263] B. A. Schmidt and V. Horsley, “Intradermal Adipocytes Mediate Fibroblast Recruitment During Skin Wound Healing,” Development (Cambridge, England) 140, no. 7 (2013): 1517–1527.

[264] T. Fiaschi, F. Magherini, T. Gamberi, P. A. Modesti, and A. Modesti, “Adiponectin as a Tissue Regenerating Hormone: More Than a Metabolic Function,” Cellular and molecular life sciences: CMLS 71, no. 10 (2014): 1917–1925.

[265] L. J. Zhang, C. F. Guerrero-Juarez, T. Hata, et al., “Innate Immunity. Dermal Adipocytes Protect Against Invasive Staphylococcus aureus Skin Infection,” Science (New York, NY) 347, no. 6217 (2015): 67–71.

[266] S. R. Coleman, “Structural Fat Grafting: More Than a Permanent Filler,” Plastic and reconstructive surgery 118, no. 3 (2006): 108s–120s.

[267] L. de Weerd, S. Weum, and S. Norderval, “Novel Treatment for Recalcitrant Rectovaginal Fistulas: Fat Injection,” International urogynecology journal 26, no. 1 (2015): 139–144.

[268] S. Norderval, L. Lundby, H. Hougaard, S. Buntzen, S. Weum, and L. de Weerd, “Efficacy of Autologous Fat Graft Injection in the Treatment of Anovaginal Fistulas,” Techniques in coloproctology 22, no. 1 (2018): 45–51.

[269] A. Dige, H. T. Hougaard, J. Agnholt, et al., “Efficacy of Injection of Freshly Collected Autologous Adipose Tissue into Perianal Fistulas in Patients With Crohn's Disease,” Gastroenterology 156, no. 8 (2019): 2208–2216.e1.

[270] S. Zaffagnini, L. Andriolo, A. Boffa, et al., “Microfragmented Adipose Tissue versus Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Prospective Randomized Controlled Trial at 2-Year Follow-Up,” The American journal of sports medicine 50, no. 11 (2022): 2881–2892.

[271] S. Laureti, P. Gionchetti, A. Cappelli, et al., “Refractory Complex Crohn's Perianal Fistulas: A Role for Autologous Microfragmented Adipose Tissue Injection,” Inflammatory bowel diseases 26, no. 2 (2020): 321–330.

[272] H. Eto, H. Kato, H. Suga, et al., “The Fate of Adipocytes After Nonvascularized Fat Grafting: Evidence of Early Death and Replacement of Adipocytes,” Plastic and reconstructive surgery 129, no. 5 (2012): 1081–1092.

[273] R. K. Khouri, R. E. Khouri, J. R. Lujan-Hernandez, K. R. Khouri, L. Lancerotto, and D. P. Orgill, “Diffusion and Perfusion: The Keys to Fat Grafting,” Plastic and reconstructive surgery Global open 2, no. 9 (2014): e220.

[274] V. M. Ramakrishnan and N. L. Boyd, “The Adipose Stromal Vascular Fraction as a Complex Cellular Source for Tissue Engineering Applications,” Tissue engineering Part B, Reviews 24, no. 4 (2018): 289–299.

[275] P. Gentile, C. Calabrese, B. De Angelis, J. Pizzicannella, A. Kothari, and S. Garcovich, “Impact of the Different Preparation Methods to Obtain Human Adipose-Derived Stromal Vascular Fraction Cells (AD-SVFs) and Human Adipose-Derived Mesenchymal Stem Cells (AD-MSCs): Enzymatic Digestion versus Mechanical Centrifugation,” International journal of molecular sciences 20, no. 21 (2019), https://doi.org/10.3390/ijms20215471.

[276] P. Bora and A. S. Majumdar, “Adipose Tissue-Derived Stromal Vascular Fraction in Regenerative Medicine: A Brief Review on Biology and Translation,” Stem cell research & therapy 8, no. 1 (2017): 145.

[277] D. Garcia-Olmo, D. Herreros, M. Pascual, et al., “Treatment of Enterocutaneous Fistula in Crohn's Disease With Adipose-Derived Stem Cells: A Comparison of Protocols With and Without Cell Expansion,” International journal of colorectal disease 24, no. 1 (2009): 27–30.

[278] K. Comella, M. Parlo, R. Daly, and K. Dominessy, “First-In-Man Intravenous Implantation of Stromal Vascular Fraction in Psoriasis: A Case Study,” Int Med Case Rep J 11 (2018): 59–64.

[279] B. Granel, A. Daumas, E. Jouve, et al., “Safety, Tolerability and Potential Efficacy of Injection of Autologous Adipose-Derived Stromal Vascular Fraction in the Fingers of Patients With Systemic Sclerosis: An Open-Label Phase I Trial,” Annals of the rheumatic diseases 74, no. 12 (2015): 2175–2182.

[280] P. Guillaume-Jugnot, A. Daumas, and J. Magalon, “Autologous Adipose-Derived Stromal Vascular Fraction in Patients With Systemic Sclerosis: 12-Month Follow-Up,” Rheumatology 55, no. 2 (2016): 301–306.

[281] A. Daumas, J. Magalon, E. Jouve, et al., “Long-Term Follow-Up After Autologous Adipose-Derived Stromal Vascular Fraction Injection Into Fingers in Systemic Sclerosis Patients,” Current research in translational medicine 65, no. 1 (2017): 40–43.

[282] N. Yokota, M. Hattori, T. Ohtsuru, et al., “Comparative Clinical Outcomes after Intra-Articular Injection With Adipose-Derived Cultured Stem Cells or Noncultured Stromal Vascular Fraction for the Treatment of Knee Osteoarthritis,” The American journal of sports medicine 47, no. 11 (2019): 2577–2583.

[283] N. Yokota, S. Lyman, H. Hanai, K. Shimomura, W. Ando, and N. Nakamura, “Clinical Safety and Effectiveness of Adipose-Derived Stromal Cell vs Stromal Vascular Fraction Injection for Treatment of Knee Osteoarthritis: 2-Year Results of Parallel Single-Arm Trials,” The American journal of sports medicine 50, no. 10 (2022): 2659–2668.

[284] T. Maeda, S. Sobajima, T. Matsumoto, et al., “Comparison of Short-Term Clinical Outcomes of Intra-Articular Injection of Micro-Fragmented Adipose Tissue and Stromal Vascular Fraction Cells for Knee Osteoarthritis Treatment: A Retrospective Single-Center Cohort Study,” Regenerative therapy 29 (2025): 91–99.

[285] A. Daumas, J. Magalon, E. Jouve, et al., “Adipose Tissue-Derived Stromal Vascular Fraction for Treating Hands of Patients With Systemic Sclerosis: A Multicentre Randomized Trial Autologous AD-SVF versus Placebo in Systemic Sclerosis,” Rheumatology 61, no. 5 (2022): 1936–1947.

[286] Z. Hong, J. Chen, S. Zhang, et al., “Intra-Articular Injection of Autologous Adipose-Derived Stromal Vascular Fractions for Knee Osteoarthritis: A Double-Blind Randomized Self-Controlled Trial,” International Orthopaedics 43, no. 5 (2019): 1123–1134.

[287] G. Maguire, “Stem Cell Therapy Without the Cells,” Communicative & integrative biology 6, no. 6 (2013): e26631.

[288] K. E. Lee, S. A. Jung, Y. H. Joo, et al., “The Efficacy of Conditioned Medium Released by Tonsil-Derived Mesenchymal Stem Cells in a Chronic Murine Colitis Model,” PLoS ONE 14, no. 12 (2019): e0225739.

[289] M. Heidari, S. Pouya, K. Baghaei, et al., “The Immunomodulatory Effects of Adipose-Derived Mesenchymal Stem Cells and Mesenchymal Stem Cells-Conditioned Medium in Chronic Colitis,” Journal of cellular physiology 233, no. 11 (2018): 8754–8766.

[290] N. Heidari, H. Abbasi-Kenarsari, S. Namaki, et al., “Adipose-Derived Mesenchymal Stem Cell-Secreted Exosome Alleviates Dextran Sulfate Sodium-Induced Acute Colitis by Treg Cell Induction and Inflammatory Cytokine Reduction,” Journal of cellular physiology 236, no. 8 (2021): 5906–5920.

[291] P. Fuenzalida, M. Kurte, C. Fernández-O'ryan, et al., “Toll-Like Receptor 3 Pre-Conditioning Increases the Therapeutic Efficacy of Umbilical Cord Mesenchymal Stromal Cells in a Dextran Sulfate Sodium-Induced Colitis Model,” Cytotherapy 18, no. 5 (2016): 630–641.

[292] J. Y. Lim, B. S. Kim, D. B. Ryu, T. W. Kim, G. Park, and C. K. Min, “The Therapeutic Efficacy of Mesenchymal Stromal Cells on Experimental Colitis Was Improved by the IFN-γ and Poly(I:C) Priming Through Promoting the Expression of Indoleamine 2,3-Dioxygenase,” Stem cell research & therapy 12, no. 1 (2021): 37.

[293] B. Zhang, R. C. Lai, W. K. Sim, A. B. H. Choo, E. B. Lane, and S. K. Lim, “Topical Application of Mesenchymal Stem Cell Exosomes Alleviates the Imiquimod Induced Psoriasis-Like Inflammation,” International journal of molecular sciences 22, no. 2 (2021), https://doi.org/10.3390/ijms22020720.

[294] Y. Zhang, J. Yan, Z. Li, J. Zheng, and Q. Sun, “Exosomes Derived From Human Umbilical Cord Mesenchymal Stem Cells Alleviate Psoriasis-Like Skin Inflammation,” Journal of Interferon & Cytokine Research 42, no. 1 (2022): 8–18.

[295] Q. Yan, H. Liu, S. Sun, et al., “Adipose-Derived Stem Cell Exosomes Loaded With icariin Alleviates Rheumatoid Arthritis by Modulating Macrophage Polarization in Rats,” Journal of nanobiotechnology 22, no. 1 (2024): 423.

[296] Q. Zhu, R. Chen, X. Wu, et al., “Bioinspired Exosome-SiO(2) Nanohybrid Therapeutic for Rheumatoid Arthritis Treatment,” Theranostics 15, no. 13 (2025): 6553–6571.

[297] Y. Jiang, J. Zhao, M. Wang, et al., “Mesenchymal Stem Cell-Derived Exosomes Can Alleviate GVHD and Preserve the GVL Effect in Allogeneic Stem Cell Transplantation Animal Models,” Frontiers in immunology 14 (2023): 1284936.

[298] E. Elgueta, C. P. Prieto, D. Hartmann, et al., “Novel Sponge Formulation of Mesenchymal Stem Cell Secretome and Hyaluronic Acid: A Safe and Effective Topical Therapy for Psoriasis vulgaris,” Stem cell research & therapy 16, no. 1 (2025): 348.

[299] M. A. Mohseni Meybodi, M. A. Nilforoushzadeh, N. KhandanDezfully, and P. Mansouri, “The Safety and Efficacy of Adipose Tissue-Derived Exosomes in Treating Mild to Moderate Plaque Psoriasis: A Clinical Study,” Life sciences 353 (2024): 122915.

[300] A. Hadizadeh, R. Akbari Asbagh, A. Heirani-Tabasi, et al., “Localized Administration of Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Refractory Perianal Fistula in Patients With Crohn's Disease: A Phase II Clinical Trial,” Diseases of the colon and rectum 67, no. 12 (2024): 1564–1575.

[301] M. Li, H. Huang, X. Wei, et al., “Clinical Investigation on Nebulized human Umbilical Cord MSC-Derived Extracellular Vesicles for Pulmonary Fibrosis Treatment,” Signal Transduct Target Ther 10, no. 1 (2025): 179.

[302] A. Habibi, A. Khosravi, M. Soleimani, M. Nejabat, M. Dara, and N. Azarpira, “Efficacy of Topical Mesenchymal Stem Cell Exosome in Sjögren's Syndrome-Related Dry Eye: A Randomized Clinical Trial,” BMC Ophthalmology [Electronic Resource] 25, no. 1 (2025): 299.

[303] D. G. Phinney, G. Kopen, W. Righter, S. Webster, N. Tremain, and D. J. Prockop, “Donor Variation in the Growth Properties and Osteogenic Potential of human Marrow Stromal Cells,” Journal of cellular biochemistry 75, no. 3 (1999): 424–436.

[304] R. Li, R. Johnson, G. Yu, D. H. McKenna, and A. Hubel, “Preservation of Cell-Based Immunotherapies for Clinical Trials,” Cytotherapy 21, no. 9 (2019): 943–957.

[305] J. R. Choi, B. Pingguan-Murphy, W. A. Wan Abas, et al., “Impact of Low Oxygen Tension on Stemness, Proliferation and Differentiation Potential of human Adipose-Derived Stem Cells,” Biochemical and biophysical research communications 448, no. 2 (2014): 218–224.

[306] P. Swamynathan, P. Venugopal, S. Kannan, et al., “Are Serum-Free and Xeno-Free Culture Conditions Ideal for Large Scale Clinical Grade Expansion of Wharton's Jelly Derived Mesenchymal Stem Cells? A Comparative Study,” Stem cell research & therapy 5, no. 4 (2014): 88.

[307] F. Tanaka, K. Tominaga, M. Ochi, et al., “Exogenous Administration of Mesenchymal Stem Cells Ameliorates Dextran Sulfate Sodium-Induced Colitis via Anti-Inflammatory Action in Damaged Tissue in Rats,” Life sciences 83, no. 23-24 (2008): 771–779.

[308] E. Eggenhofer, V. Benseler, A. Kroemer, et al., “Mesenchymal Stem Cells Are Short-Lived and Do Not Migrate Beyond the Lungs After Intravenous Infusion,” Frontiers in immunology 3 (2012): 297.

[309] U. M. Fischer, M. T. Harting, F. Jimenez, et al., “Pulmonary Passage Is a Major Obstacle for Intravenous Stem Cell Delivery: The Pulmonary First-Pass Effect,” Stem cells and development 18, no. 5 (2009): 683–692.

[310] M. Wang, C. Liang, H. Hu, et al., “Intraperitoneal Injection (IP), Intravenous Injection (IV) or Anal Injection (AI)? Best Way for Mesenchymal Stem Cells Transplantation for Colitis,” Scientific reports 6 (2016): 30696.

[311] D. García-Sánchez, D. Fernández, J. C. Rodríguez-Rey, and F. M. Pérez-Campo, “Enhancing Survival, Engraftment, and Osteogenic Potential of Mesenchymal Stem Cells,” World journal of stem cells 11, no. 10 (2019): 748–763.

[312] S. Yu, S. Yu, H. Liu, N. Liao, and X. Liu, “Enhancing Mesenchymal Stem Cell Survival and Homing Capability to Improve Cell Engraftment Efficacy for Liver Diseases,” Stem cell research & therapy 14, no. 1 (2023): 235.

[313] Y. Tanaka, S. Kurosawa, K. Tajima, et al., “Analysis of Non-Relapse Mortality and Causes of Death Over 15 Years Following Allogeneic Hematopoietic Stem Cell Transplantation,” Bone marrow transplantation 51, no. 4 (2016): 553–559.

[314] S. A. Sonwalkar, R. M. James, T. Ahmad, et al., “Fulminant Crohn's Colitis After Allogeneic Stem Cell Transplantation,” Gut 52, no. 10 (2003): 1518–1521.

[315] S. Giardino, C. Bava, S. Arrigo, et al., “Thalidomide as Treatment of Crohn-Like Disease Occurred After Allogeneic Hematopoietic Stem Cell Transplantation in a Pediatric Patient,” Pediatric transplantation 25, no. 3 (2021): e13941.

[316] C. Melzer, J. von der Ohe, and R. Hass, “Enhanced Metastatic Capacity of Breast Cancer Cells After Interaction and Hybrid Formation With Mesenchymal Stroma/Stem Cells (MSC),” Cell communication and signaling: CCS 16, no. 1 (2018): 2.

[317] N. V. Kim, G. McErlean, S. Yu, I. Kerridge, M. Greenwood, and R. A. Lourenco, “Healthcare Resource Utilization and Cost Associated With Allogeneic Hematopoietic Stem Cell Transplantation: A Scoping Review,” Transplantation and Cellular Therapy 30, no. 5 (2024): 542.e1–542.e29.

[318] K. N. Gottschlich, Z. Zolic-Karlsson, E. Aas, et al., “Healthcare Utilization and Costs Associated With Autologous Haematopoietic Stem Cell Transplantation in Norwegian Patients With Relapsing Remitting Multiple Sclerosis,” Multiple sclerosis and related disorders 84 (2024): 105507.

[319] S. Johnson, J. S. Hoch, W. J. Halabi, J. Ko, J. Nolta, and M. Dave, “Mesenchymal Stem/Stromal Cell Therapy Is More Cost-Effective than Fecal Diversion for Treatment of Perianal Crohn's Disease Fistulas,” Frontiers in immunology 13 (2022): 859954.

[320] A. MacPherson and J. Kimmelman, “Ethical Development of Stem-Cell-Based Interventions,” Nature medicine 25, no. 7 (2019): 1037–1044.

[321] D. Sipp, P. G. Robey, and L. Turner, “Clear up this Stem-Cell Mess,” Nature 561, no. 7724 (2018): 455–457.

[322] D. J. Prockop, “Repair of Tissues by Adult Stem/Progenitor Cells (MSCs): Controversies, Myths, and Changing Paradigms,” Molecular therapy: the journal of the American Society of Gene Therapy 17, no. 6 (2009): 939–946.

[323] T. J. Hwang, J. M. Franklin, C. T. Chen, et al., “Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines,” Journal of clinical oncology: official journal of the American Society of Clinical Oncology 36, no. 18 (2018): 1805–1812.

[324] A. I. Caplan and M. D. West, “Progressive Approval: A Proposal for a New Regulatory Pathway for Regenerative Medicine,” Stem cells translational medicine 3, no. 5 (2014): 560–563.

[325] Q. Gu, J. Wang, L. Wang, et al., “Accreditation of Biosafe Clinical-Grade Human Embryonic Stem Cells According to Chinese Regulations,” Stem cell reports 9, no. 1 (2017): 366–380.

[326] A. Rosemann and M. Sleeboom-Faulkner, “New Regulation for Clinical Stem Cell Research in China: Expected Impact and Challenges for Implementation,” Regenerative medicine 11, no. 1 (2016): 5–9.

[327] Z. Master, K. R. W. Matthews, and M. Abou-El-Enein, “Unproven Stem Cell Interventions: A Global Public Health Problem Requiring Global Deliberation,” Stem cell reports 16, no. 6 (2021): 1435–1445.

[328] K. Takashima, M. Morrison, and J. Minari, “Reflection on the Enactment and Impact of Safety Laws for Regenerative Medicine in Japan,” Stem cell reports 16, no. 6 (2021): 1425–1434.

[329] T. Caulfield and B. Murdoch, “Regulatory and Policy Tools to Address Unproven Stem Cell Interventions in Canada: The Need for Action,” BMC medical ethics 20, no. 1 (2019): 51.

[330] M. Hansen, M. von Lindern, E. van den Akker, and E. Varga, “Human-Induced Pluripotent Stem Cell-Derived Blood Products: State of the Art and Future Directions,” FEBS letters 593, no. 23 (2019): 3288–3303.

[331] S. H. Chiou, H. K. A. Ong, S. J. Chou, et al., “Current Trends and Promising Clinical Utility of IPSC-Derived MSC (iMSC),” Progress in molecular biology and translational science 199 (2023): 131–154.

[332] D. K. W. Ocansey, B. Pei, Y. Yan, et al., “Improved Therapeutics of Modified Mesenchymal Stem Cells: An Update,” Journal of translational medicine 18, no. 1 (2020): 42.

[333] W. Zhu, Q. Chen, Y. Li, J. Wan, J. Li, and S. Tang, “HIF-1α-Overexpressing Mesenchymal Stem Cells Attenuate Colitis by Regulating M1-Like Macrophages Polarization Toward M2-Like Macrophages,” Biomedicines 11, no. 3 (2023), https://doi.org/10.3390/biomedicines11030825.

[334] L. Zhou, F. Yan, R. Jiang, J. Liu, L. Cai, and Y. Wang, “Administration of Nrf-2-Modified Hair-Follicle MSCs Ameliorates DSS-Induced Ulcerative Colitis in Rats,” Oxidative medicine and cellular longevity 2021 (2021): 9930187.

[335] X. Li, Q. Wang, L. Ding, et al., “Intercellular Adhesion Molecule-1 Enhances the Therapeutic Effects of MSCs in a Dextran Sulfate Sodium-Induced Colitis Models by Promoting MSCs Homing to Murine Colons and Spleens,” Stem cell research & therapy 10, no. 1 (2019): 267.

[336] X. Cao, L. Duan, H. Hou, et al., “IGF-1C Hydrogel Improves the Therapeutic Effects of MSCs on Colitis in Mice Through PGE(2)-Mediated M2 Macrophage Polarization,” Theranostics 10, no. 17 (2020): 7697–7709.

[337] A. Gonzalez-Pujana, A. Beloqui, J. Javier Aguirre, M. Igartua, E. Santos-Vizcaino, and R. Maria Hernandez, “Mesenchymal Stromal Cells Encapsulated in Licensing Hydrogels Exert Delocalized Systemic Protection Against Ulcerative Colitis via Subcutaneous Xenotransplantation,” European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV 172 (2022): 31–40.

[338] A. B. Dietz, E. J. Dozois, J. G. Fletcher, et al., “Autologous Mesenchymal Stem Cells, Applied in a Bioabsorbable Matrix, for Treatment of Perianal Fistulas in Patients With Crohn's Disease,” Gastroenterology 153, no. 1 (2017): 59–62. e2.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.